CIC
RVNC

Carnegie Investment Counsel’s Revance Therapeutics, Inc. RVNC Stock Holding History

Carnegie Investment Counsel’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,400
Closed -$234K – 519
2021
Q3 		$234K Sell
8,400
-1,400
-14% -$40K 0.01% 434
2021
Q2 		$290K Sell
9,800
-4,150
-30% -$120K 0.01% 400
2021
Q1 		$390K Sell
13,950
-1,300
-9% -$36K 0.02% 345
2020
Q4 		$432K Buy
+15,250
New +$395K 0.02% 317

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Carnegie Investment Counsel's RVNC Position: Q4 2021 in Review

Carnegie Investment Counsel sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 8,400 shares — an estimated $234K sold.

Carnegie Investment Counsel first reported a position in RVNC in Q4 2020 and held it in 4 quarters. The position peaked at $432K in Q4 2020. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • Carnegie Investment Counsel reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Carnegie Investment Counsel sold 8,400 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $234K.
  • Carnegie Investment Counsel first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 4 quarters.
  • Carnegie Investment Counsel's Revance Therapeutics, Inc. position peaked at $432K in Q4 2020.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Carnegie Investment Counsel's 13F filing for Q4 2021, filed 21 Jan 2022.